Filing Flows › Vanda Pharmaceuticals (VNDA) › Guidance history
Vanda Pharmaceuticals (VNDA) guidance history: what it guided and what it reported
Vanda Pharmaceuticals gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $240M–$290M (May 6, 2026) → reaffirmed $240M–$290M (Aug 5, 2026) | — | to be reported | — |
The latest quarter
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
Questions
Does Vanda Pharmaceuticals beat its guidance?
Vanda Pharmaceuticals gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it 0 times.
How often does Vanda Pharmaceuticals raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since May 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.